The Muscular Dystrophy Association (MDA) welcomes the U.S. Food and Drug Administration (FDA) approval of the expanded indication of Alexion/AstraZeneca’s eculizumab (Soliris) for pediatric patients ...

Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) ongoing; top-line results on track for 2H’25Phase 3 CAPTIVATE trial of ...

Generalized myasthenia gravis (gMG) affects most patients through a handful of well-characterized neuromuscular junction ...

Seismic Therapeutic, Inc., the machine learning immunology company, today announced the dosing of the first healthy subject ...

Anti-acetylcholine receptor antibody (AChR-Ab) titers and the AChR-Ab rates of change correlated with myasthenia gravis disease severity scores in a recent study. Using anti-acetylcholine receptor ...

On World Rare Diseases Day, read on to learn more about Myasthenia Gravis, a complex autoimmune disorder that requires careful management. Early diagnosis and appropriate treatment can help ...

antibodies. Higher Quantitative Myasthenia Gravis-Revised (QMG) scores, indicating more severe disease based on clinician ratings, have been associated with frequent exacerbations. New data from ...

Argenx had cash, cash equivalents, and other short-term investments totaling $3.4 billion as of the end of 2024, making it well-positioned to continue funding its pipeline and commercialization ...

Unlike the monoclonal antibodies eculizumab and ravulizumab ... that are integral to the pathogenesis of generalized myasthenia gravis," noted Richard Nowak, MD, MS, of Yale University in New ...

Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Get Free Report) has received a consensus recommendation of “Buy” from the nine ...

We met the primary end point, which was to show improvement in MG-ADL score—that's myasthenia gravis activities of daily living score—at 6 months, and it was in a broad group of antibody ...